1. Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis.
- Author
-
Chen P, Li Y, Huang H, Li Y, Huang X, Chen Z, Liu X, Qiu L, Ou C, Huang Z, Lin Z, Ran H, and Liu W
- Subjects
- Adolescent, Adrenal Cortex Hormones therapeutic use, Adult, Aged, Cell Count, Child, Child, Preschool, Female, Flow Cytometry, Humans, Immune Tolerance immunology, Immunophenotyping, Immunosuppressive Agents therapeutic use, Leflunomide therapeutic use, Male, Middle Aged, Myasthenia Gravis drug therapy, Young Adult, Dendritic Cells immunology, Myasthenia Gravis immunology
- Abstract
Although it is well documented that circulating dendritic cells (DCs) have specialized features during many kinds of physiological and pathological conditions, there are few reports about the features of DCs in the peripheral blood of myasthenia gravis (MG) patients. We investigated the quantitative and component features of DCs and their implications in MG. Peripheral blood samples from different kinds of MG patients were collected and their clinical characteristics were recorded. Using flow cytometry, we distinguished circulating DC subsets [plasmacytoid DCs (pDCs) and myeloid DCs (mDCs)] and enumerated their densities in peripheral blood. Absolute numbers of circulating pDCs were significantly decreased in naïve MG patients compared with healthy controls, resulting in a markedly lower ratio of the pDC to mDC percentage in total circulating DCs (pDCs/mDCs), suggesting an imbalance in the proportions of the two main circulating DC subsets. The clinical status of MG patients was improved after drug treatment, together with increased pDCs/mDCs. In a longitudinal follow-up, we observed that circulating mDCs were significantly reduced after 1 month of therapy with a corticosteroid and immunosuppressant, resulting in recovery of pDCs/mDCs. Although the exact meaning of the proportion change in circulating DC subsets is unknown, pDCs/mDCs might reflect the balance between the autoimmune response and immune tolerance of a patient. Moreover, changes in pDCs/mDCs during treatment might be a promising marker to predict the efficacy of a specific drug used for MG patients., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF